SALT LAKE CITY, March 14, 2018 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a specialty pharmaceutical company, announced today
that Dr. Mahesh Patel, Chairman,
President and CEO, will provide a corporate overview at the
Oppenheimer 28th Annual Healthcare Conference, being
held March 20th –
21st at the Westin Grand Central Hotel in New York City.
Presentation
Details
|
Date:
|
Wednesday, March
21st
|
Time:
|
3:55pm Eastern
Time
|
Location:
|
Westin Grand Central
Hotel, Consulate Ballroom
|
Webcast:
|
https://veracast.com/webcasts/opco/healthcare2018/93216258627.cfm
|
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's
health using its proprietary drug delivery technologies. Lipocine's
clinical development pipeline includes three development programs
TLANDO, LPCN 1111 and LPCN 1107. TLANDO, a novel oral prodrug
of testosterone containing testosterone undecanoate, is designed to
help restore normal testosterone levels in hypogonadal men. TLANDO
was well tolerated and met the primary efficacy end-points in Phase
3 testing with twice daily dosing and is currently under FDA
review. LPCN 1111, a novel oral prodrug of testosterone,
originated and is being developed by Lipocine as a next-generation
oral testosterone product with potential for once-daily dosing and
is currently in Phase 2 testing. LPCN 1107 is potentially the
first oral hydroxyprogesterone caproate product candidate indicated
for the prevention of recurrent preterm birth, is currently in
Phase 2 testing and has been granted orphan drug designation by the
FDA. For more information, please visit www.lipocine.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-oppenheimer-28th-annual-healthcare-conference-300613266.html
SOURCE Lipocine Inc.